FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3102156944> ?p ?o ?g. }

• W3102156944 endingPage "122.e1" @default.
• W3102156944 startingPage "112" @default.
• W3102156944 abstract "Binge-eating disorder (BED), the most prevalent eating disorder, is associated strongly with obesity and functional impairments. Few evidence-based treatments for BED exist; a pharmacotherapy effective in reducing both binge eating and weight needs to be identified. This placebo-controlled double-blind pilot RCT evaluated the acute effects of naltrexone + bupropion (NB) on BED with obesity and examined the longer-term effects through 6-month follow-up after the discontinuation of medication.Twenty-two adult patients with BED were randomized to receive 12 weeks of double-blind treatment with fixed-dose NB (naltrexone + bupropion XL 50/300 mg) or placebo. Independent (blinded) researcher-clinicians evaluated patients at major outcome time points (baseline, posttreatment, and 6-month follow-up after the treatment period); patients were also evaluated for the tracking of course/tolerability throughout treatments and at 3-month follow-up. Primary outcomes were changes from baseline in binge-eating frequency and percentage weight. Secondary outcomes were changes in eating-disorder psychopathology and depression.A total of 22 patients were enrolled (86.4% women; mean age, 50.4 years), with 77.3% of patients completing treatments; completion rates (NB, 83.3%; placebo, 70.0%) and adverse events did not differ significantly between NB and placebo. Analyses revealed significant reductions from baseline in binge-eating, eating-disorder psychopathology, depression, and weight during treatment, but these changes with NB did not differ significantly from those with placebo. The percentage of patients who attained 3% weight loss was significantly greater with NB than with placebo (45.5% vs 0%); weight-loss and binge-eating reductions were significantly correlated in the group that received NB. At 6-month follow-up, outcomes remained improved relative to baseline, with no significant differences between NB and placebo.The findings from this pilot RCT suggest that NB was well-tolerated in these patients with BED and comorbid obesity. Most outcomes were not statistically different between NB and placebo. A larger-scale, adequately powered RCT is needed for determining the efficacy of NB in the treatment of BED. ClinicalTrials.gov identifier: NCT02317744." @default.
• W3102156944 created "2020-11-23" @default.
• W3102156944 creator A5016331294 @default.
• W3102156944 creator A5052366236 @default.
• W3102156944 creator A5062341708 @default.
• W3102156944 creator A5078977437 @default.
• W3102156944 date "2021-01-01" @default.
• W3102156944 modified "2023-10-15" @default.
• W3102156944 title "Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study" @default.
• W3102156944 cites W1425537810 @default.
• W3102156944 cites W1506453366 @default.
• W3102156944 cites W1994603938 @default.
• W3102156944 cites W1994971564 @default.
• W3102156944 cites W1997115741 @default.
• W3102156944 cites W2004503646 @default.
• W3102156944 cites W2008104283 @default.
• W3102156944 cites W2012404877 @default.
• W3102156944 cites W2025831187 @default.
• W3102156944 cites W2032132493 @default.
• W3102156944 cites W2036089668 @default.
• W3102156944 cites W2070505803 @default.
• W3102156944 cites W2072833030 @default.
• W3102156944 cites W2087145870 @default.
• W3102156944 cites W2110438413 @default.
• W3102156944 cites W2113572448 @default.
• W3102156944 cites W2141647992 @default.
• W3102156944 cites W2148457688 @default.
• W3102156944 cites W2153580775 @default.
• W3102156944 cites W2161407622 @default.
• W3102156944 cites W2432501512 @default.
• W3102156944 cites W2435725593 @default.
• W3102156944 cites W2581985549 @default.
• W3102156944 cites W2755066804 @default.
• W3102156944 cites W2801697874 @default.
• W3102156944 cites W2905971773 @default.
• W3102156944 cites W2914520605 @default.
• W3102156944 cites W2961364940 @default.
• W3102156944 cites W3037625818 @default.
• W3102156944 doi "https://doi.org/10.1016/j.clinthera.2020.10.010" @default.
• W3102156944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7902424" @default.
• W3102156944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33218742" @default.
• W3102156944 hasPublicationYear "2021" @default.
• W3102156944 type Work @default.
• W3102156944 sameAs 3102156944 @default.
• W3102156944 citedByCount "23" @default.
• W3102156944 countsByYear W31021569442021 @default.
• W3102156944 countsByYear W31021569442022 @default.
• W3102156944 countsByYear W31021569442023 @default.
• W3102156944 crossrefType "journal-article" @default.
• W3102156944 hasAuthorship W3102156944A5016331294 @default.
• W3102156944 hasAuthorship W3102156944A5052366236 @default.
• W3102156944 hasAuthorship W3102156944A5062341708 @default.
• W3102156944 hasAuthorship W3102156944A5078977437 @default.
• W3102156944 hasBestOaLocation W31021569441 @default.
• W3102156944 hasConcept C118552586 @default.
• W3102156944 hasConcept C123273963 @default.
• W3102156944 hasConcept C126322002 @default.
• W3102156944 hasConcept C139719470 @default.
• W3102156944 hasConcept C142724271 @default.
• W3102156944 hasConcept C162324750 @default.
• W3102156944 hasConcept C168563851 @default.
• W3102156944 hasConcept C170493617 @default.
• W3102156944 hasConcept C197934379 @default.
• W3102156944 hasConcept C204787440 @default.
• W3102156944 hasConcept C27081682 @default.
• W3102156944 hasConcept C2776394216 @default.
• W3102156944 hasConcept C2776867660 @default.
• W3102156944 hasConcept C2777556793 @default.
• W3102156944 hasConcept C2777843972 @default.
• W3102156944 hasConcept C2777972943 @default.
• W3102156944 hasConcept C2777978298 @default.
• W3102156944 hasConcept C2778202721 @default.
• W3102156944 hasConcept C2778375690 @default.
• W3102156944 hasConcept C2778715236 @default.
• W3102156944 hasConcept C2779908668 @default.
• W3102156944 hasConcept C2781063702 @default.
• W3102156944 hasConcept C2781426410 @default.
• W3102156944 hasConcept C511355011 @default.
• W3102156944 hasConcept C544821477 @default.
• W3102156944 hasConcept C71924100 @default.
• W3102156944 hasConceptScore W3102156944C118552586 @default.
• W3102156944 hasConceptScore W3102156944C123273963 @default.
• W3102156944 hasConceptScore W3102156944C126322002 @default.
• W3102156944 hasConceptScore W3102156944C139719470 @default.
• W3102156944 hasConceptScore W3102156944C142724271 @default.
• W3102156944 hasConceptScore W3102156944C162324750 @default.
• W3102156944 hasConceptScore W3102156944C168563851 @default.
• W3102156944 hasConceptScore W3102156944C170493617 @default.
• W3102156944 hasConceptScore W3102156944C197934379 @default.
• W3102156944 hasConceptScore W3102156944C204787440 @default.
• W3102156944 hasConceptScore W3102156944C27081682 @default.
• W3102156944 hasConceptScore W3102156944C2776394216 @default.
• W3102156944 hasConceptScore W3102156944C2776867660 @default.
• W3102156944 hasConceptScore W3102156944C2777556793 @default.
• W3102156944 hasConceptScore W3102156944C2777843972 @default.
• W3102156944 hasConceptScore W3102156944C2777972943 @default.
• W3102156944 hasConceptScore W3102156944C2777978298 @default.
• W3102156944 hasConceptScore W3102156944C2778202721 @default.

• next